The biomarkers predictive of anti-PD-1 response in gastric cancer at this stage include PD-L1 expression, the microsatellite instability (MSI)/mismatch repair (MMR) status, Epstein-Barr virus (EBV) infection, and the tumor mutation burden (TMB) [5, 6]. The gene discussed is CD274; the disease is neoplasm.